Would you consider using immunotherapy in mismatch repair proficient metastatic colorectal cancer with PDL1/PDL2 gene amplification?

This is a very interesting question with limited data.

PD-L1 amplification is rarely seen in the clinic. The largest study to date (with 118 187 tumor sample) suggested 0.7% PD-L1 amplification in all solid tumors with <0.02% in colon or rectal cancers (Goodman et al., PMID 29902298). Interestingly,...